Reprising the role of CD4 cell count in HIV programmes-Reference-Cited by-同舟云学术

Reprising the role of CD4 cell count in HIV programmes

Published:2017-09 Issue:9 Volume:4 Page:e377-e378
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Peeling Rosanna W,Ford Nathan

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference8 articles.

1. The future role of CD4 cell count for monitoring antiretroviral therapy;Ford;Lancet Infect Dis,2015

2. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study;Jani;Lancet,2011

3. Effect of point-of-care CD4 cell count results on linkage to care and antiretroviral initiation during a home-based HIV testing campaign: a non-blinded, cluster-randomised trial;Desai;Lancet HIV,2017

4. Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review;Govindasamy;AIDS,2012

5. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A profile of the Visitect® CD4 and Visitect® CD4 advanced disease for management of people living with HIV;Expert Review of Molecular Diagnostics;2022-03-04

2. Point-of-care CD4 testing: Differentiated care for the most vulnerable;Journal of Global Health;2022-02-05

3. Effects of National Adoption of Treat-All Guidelines on Pre-Antiretroviral Therapy (ART) CD4 Testing and Viral Load Monitoring After ART initiation: A Regression Discontinuity Analysis;Clinical Infectious Diseases;2021-03-09

4. Utility of CD4 count measurement in the era of universal antiretroviral therapy: an analysis of routine laboratory data in Botswana;HIV Medicine;2020-09-02

5. Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV;Journal of Virus Eradication;2019-10